sitagliptin glp 1 agonist πππππ¬π π©π¨π¬π’ππ’π¨π§ π¨π πππ-π π’π§π‘π’ππ’ππ¨π«π¬ (π.π ., π¬π’πππ π₯π’π©ππ’π§, π¬ππ±ππ π₯π’π©ππ’π§, π₯π’π§ππ π₯π’π©ππ’π§, ππ₯π¨π π₯π’π©ππ’π§, π―π’π₯πππ π₯π’π©ππ’π§) π’π§ ππ‘π ππππ πππ ππππ§πππ«ππ¬ π¨π GLP-1-based therapies for type 2
Description
No safety signals related to DR were reported in the EXSCEL (Exenatide Study of Cardiovascular Event Lowering) and the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trials
[DOI] [PubMed] 71.Gadde KM, Allison DB, Ryan DH, et al
Weber, M
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity A Phase 2 Trial
Top Companies in the GLP-1 Receptor Agonist Amneal Pharmaceuticals Ascendis Pharma AstraZeneca Boehringer Ingelheim Eli Lilly & Company Hansoh Pharma Innovent Biologics Merck Metsera, Inc
The plans we represent do not discriminate on the basis of race, color, national origin, age, disability, or sex
